Phaseline

Targets › TOPOISOMERASE

TOPOISOMERASE: drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 3; Infectious disease, Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on TOPOISOMERASE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Huashan HospitalLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, TOPOISOMERASEPhase 3Multidrug Resistant Tuberculosis; Drug-resistant TuberculosisDec 2026
University of SydneyBleomycin Sulfate
DNA damage induction via bleomycin-metal complex formation and strand breaking
TOPOISOMERASEPhase 3Germ Cell TumorDec 2029

Conditions

Multidrug Resistant Tuberculosis (1) Drug-resistant Tuberculosis (1) Germ Cell Tumor (1)

Modalities

mixed (1)

Companies

Huashan Hospital (1) University of Sydney (1)

Related targets

GYRA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.